Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.35 | N/A | -58.45% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.35 | N/A | -58.45% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach in their commentary. They emphasized the importance of their ongoing projects but did not provide specific future expectations.
Management did not provide specific guidance for future quarters.
The company is focused on ongoing development and regulatory processes.
Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a decline in stock price by 4.91%. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term performance and strategic direction. The stock's reaction indicates that investors are cautious following these results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EOG RES INC
Oct 29, 2007